Skip to main content

Advertisement

Table 1 Baseline characteristics of 124 HIV/TB co-infected patients with CYP2B6-G516T genotypes in efavirenz and nevirapine groups.

From: Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

Baseline characteristics Efavirenz group (n = 65) Nevirapine group (n = 59)
  CYP2B6 -G516T CYP2B6 -G516T
  GG GT TT p-value GG GT TT p-value
  n = 25 n = 31 n = 9   n = 26 n = 31 n = 2  
Sex Male: Female 16: 9 21: 10 5: 4 0.795 17: 9 22: 9 1: 1 0.707
Age
years, mean (SD)
36.48
(8.08)
35.68
(8.82)
35
(6.63)
0.882 36.48
(8.08)
35.68
(8.82)
35
(6.63)
0.467
Body weight
kg, mean (SD)
52.9
(1.87)
53.94
(1.89)
52.22
(3.04)
0.872 54.62
(2.06)
54.7
(1.52)
46.5
(6.5)
0.489
Alkaline phosphatase,
U/L, mean (SD)
149.2
(18.38)
137.1
(16.91)
233.9
(68.45)
0.085 150.25
(28.9)
113.97
(11.1)
125
(4)
0.458
Aspartate aminotransferase U/L, mean (SD) 32.8
(2.35)
40.48
(3.32)
43.22
(10.21)
0.202 48.54
(7.31)
35.58
(2.99)
26
(1)
0.167
Alanine aminotransferase, U/L, mean (SD) 27.0
(3.05)
28.55
(2.89)
31.22
(8.89)
0.821 29.81
(3.95)
27.94
(3.57)
23.5
(5.5)
0.877
Total bilirubin,
mg/dL, mean (SD)
4.9
(4.34)
0.56
(0.55)
0.43
(0.07)
0.452 2.97
(2.4)
1.13
(0.57)
0.6
(0.1)
0.703
Direct bilirubin,
mg/dL, mean (SD)
0.45
(0.14)
0.37
(0.12)
0.21
(0.05)
0.631 0.28
(0.047)
0.52
(0.199)
0.30
(0.1)
0.568
CD4 count,
cells/μl, median (IQR)
41
(18-102)
54
(24-120)
67
(12.5-168)
0.818 35.5
(23.5-97)
45
(25-113)
30.5
(23)
0.595
Log Plasma HIV-1 viral load
median (IQR)
5.90
(5.57-6.0)
5.93
(5.39-6.0)
5.64
(5.50-6.0)
0.729 5.86
(5.46-6.0)
5.60
(5.41-5.81)
5.80
(Q1 = 5.59)
0.041*
  1. * Statistically significant by Kruskal-Wallis test. SD: standard deviation. IQR: interquartile range.